PROCLAIM Consortium

Overview

The widespread use of the atypical antipsychotic, clozapine, has been limited due to considerable risks of rare but potentially fatal adverse side effects. Among these adverse effects, cardiac side effects such as myocarditis are under-appreciated despite their association with increased risk of death. Unfortunately, our ability to identify those at greatest risk for clozapine-associated cardiac side effects is poor.

In response to this gap in knowledge, we have established the Pharmacogenetics of Clozapine-Induced Myocarditis (PROCLAIM) Consortium. The PROCLAIM Consortium is uniting investigators around the world to uncover genomic markers that could be used preemptively by clinicians to identify those patients at highest risk for myocarditis from clozapine therapy and identify the mechanism by which clozapine induces myocardial inflammation and damage.

We invite all clinicians and/or investigators who have cared for and/or studied individuals that have developed myocarditis following clozapine exposure to join the PROCLAIM Consortium. We are particularly interested in members who can contribute samples and/or genomic data that would enable pooled analyses to be performed. Please contact us if you are interested in becoming a site.

History

The PROCLAIM Consortium was initiated in 2017 by Dr Chad Bousman and Prof Christos Pantelis at the University of Melbourne. The first nine participants were recruited from the Adult Mental Health Rehabilitation Unit at Sunshine Hospital in Melbourne, Australia. In late 2017, Dr Bousman and the PROCLAIM Consortium relocated to the University of Calgary, maintaining the University of Melbourne as a study site. Currently there are 14 sites covering Australia, Canada, Turkey and the US (see below for site details and investigators affiliated with the study).

Funding

University of Melbourne Establishment Grant (2017)

University of Calgary, Cumming School of Medicine (2017-2020)

University of Calgary, VPR Catalyst Grant (2021)

Study Team

Principal Investigator:

Chad Bousman, MPH, PhD

University of Calgary

Co-Investigators:

University of Calgary

Steven Greenway, MSC, MD, FRCPC

Rory Sellmer, BPE, MD, FRCPC

David Crockford, MD, FRCPC, DABPN, FAPA, FCPA

University of Toronto, Centre for Addictions & Mental Health

Gary Remington, MD, PhD

University of Ottawa

Jess Fiedorowicz, M.D., Ph.D.

William Osler Health System

Shailesh Nadkarni, MBBS, MHSA

Amlan Das, MD

Charles Ohene-Darkoh, MD

University of British Columbia

Robert Stowe, MD, ABPN, FRCPC

University of Saskatchewan

Rohit Lodhi, PhD, FRANZCP, MRCPsych, MD Psych, D.P.M

University of Melbourne

Christos Pantelis, MBBS, MRCPsych, MD, FRANZCP

Naveen Thomas, MBBS

Mahesh Jayaram, MBBS, DPM, MMedSc

Monash University

Kathlyn Ronaldson, BSc, MSc, DPhil, MPH

John McNeil, MBBS, MSc, PhD, FRACP, FAFPHM

Paul Lacaze, PhD

University of New South Wales, Neuroscience Research Australia

Cynthia Shannon Weickert, BA, Mphil, PhD

University of Queensland

Dan Siskind, MD, PhD

Karl Winckel, BPharm

The University of Newcastle

Murray Cairns, PhD

James Cook University

Tahnee L Bridson, MBBS BMedSc

Harvard University

Kevin J Li, MD

Lynn DeLisi, MD

Ronald Gurerra, MD

Jerry Fleming, MPH

Hacettepe University (Turkey)

A. Elif Anil Yagcioglu, MD